The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms

Melioli, Giovanni; Bonifazi, F.; Bonini, Sergio; Maggi, Enrico; Mussap, Michele; Passalacqua, G.; Rossi, Enzo Renato; Vacca, Angelo; Canonica, Giorgio Walter

doi:10.1016/j.clinbiochem.2011.05.007

Cited by 92 publications

(128 citation statements)

References 13 publications

Supporting

Mentioning

122

Contrasting

Order By: Relevance

“…Inter-assay CV of ISAC 103 was > 100%, 33% and 13.2% for Low, Medium and High ISU-E categories, respectively [17]; however, definitions of the Low and Medium categories for ISAC 103 differ from the current definitions for ISAC 112. These previous estimates of total variation were based on within-and between-assay estimates of variability obtained using a reproducibility study where all assays were run at one site [17]. In the present study the categoryspecific estimates of variation ranged from 22 to 27% and the overall estimate, CV Total , was 25.5%.…”

Section: Discussionmentioning

confidence: 97%

“…Fluorescence intensity is measured by a microarray scanner, converted to arbitrary concentration units, and is then displayed both in arbitrary units ISAC Standardized Units for IgE (ISU-E), being internally cross-calibrated to ImmunoCAP singleplex kU A /l, and as semi-quantitative values (classes). The technical and clinical performances of the ISAC 112 have been validated in several studies that -depending on the allergen component -report comparable results to quantitative singleplex ImmunoCAP allergen component tests [3,[10][11][12][13][14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study

Hage¹,

Schmid‐Grendelmeier²,

Skevaki³

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study

Hage¹,

Schmid‐Grendelmeier²,

Skevaki³

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…The first allergen microarray [Immuno Solid-Phase Allergen Chip (ISAC)] was described in 2002 [23]. Since then the assay was improved, the number of components increased and its clinical use become widespread [18,[24][25][26]. Recently, other platforms were developed and described: the MedALL [27] and the Microtest [28].…”

Section: Multiplexed Diagnostics (Mpd)mentioning

confidence: 99%

Molecular diagnosis and precision medicine in allergy management

Riccio

Ferrari

Chiappori

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

Precision medicine (PM) can be defined as a structural model aimed at customizing healthcare, with medical decisions/products tailored on an individual patient at a highly detailed level. In this sense, allergy diagnostics based on molecular allergen components allows to accurately define the patient's IgE repertoire. The availability of highly specialized singleplexed and multiplexed platforms support allergists with an advanced diagnostic armamentarium. The therapeutic intervention, driven by the standard diagnostic approach, but further supported by these innovative tools may result, for instance, in a more appropriate prescription of allergen immunotherapy (AIT). Also, the phenotyping of patients, which may have relevant effects on the treatment strategy, could be take advantage by the molecular allergy diagnosis.

show abstract

“…It has many advantages and results are close but not identical to classical immunoassays [10] (WAO Position Paper, in press). However, for some allergens [11][12][13] and for low IgE levels [14] it may not be sufficiently sensitive. Moreover, important allergens are not included on the ImmunoCAP ISAC chip.…”

Section: Introductionmentioning

confidence: 99%

Advances in allergen-microarray technology for diagnosis and monitoring of allergy: The MeDALL allergen-chip

Lupinek

Wollmann

Baar

et al. 2014

Methods

225

259

View full text Add to dashboard Cite

Allergy diagnosis based on purified allergen molecules provides detailed information regarding the individual sensitization profile of allergic patients, allows monitoring of the development of allergic disease and of the effect of therapies on the immune response to individual allergen molecules. Allergen microarrays contain a large variety of allergen molecules and thus allow the simultaneous detection of allergic patients' antibody reactivity profiles towards each of the MeDALL is a European research program in which allergen microarray technology is used for the monitoring of the development of allergic disease in childhood, to draw a geographic map of the recognition of clinically relevant allergens in different populations and to establish reactivity profiles which are associated with and predict certain disease manifestations. We describe technical advances of the MeDALL allergen-chip regarding specificity, sensitivity and its ability to deliver test results which are close to in vivo reactivity. In addition, the usefulness and numerous advantages of allergen microarrays for allergy research, refined allergy diagnosis, monitoring of disease, of the effects of therapies, for improving the prescription of specific immunotherapy and for prevention are discussed. Europe PMC Funders Group

show abstract

The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms

Cited by 92 publications

References 13 publications

Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study

Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study

Molecular diagnosis and precision medicine in allergy management

Advances in allergen-microarray technology for diagnosis and monitoring of allergy: The MeDALL allergen-chip

Contact Info

Product

Resources

About